These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 36964557)

  • 41. Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups.
    Bi Y; Lu S; Tang J; Du L; Ji L
    Diabetes Ther; 2024 May; 15(5):1125-1137. PubMed ID: 38494574
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management.
    Sinha R; Papamargaritis D; Sargeant JA; Davies MJ
    J Obes Metab Syndr; 2023 Mar; 32(1):25-45. PubMed ID: 36750526
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data.
    Trautmann ME; Han J; Ruggles J
    Clin Ther; 2016 Jun; 38(6):1464-1473. PubMed ID: 27126504
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials.
    Permana H; Yanto TA; Hariyanto TI
    Diabetes Metab Syndr; 2022 Nov; 16(11):102640. PubMed ID: 36274410
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3.
    Viljoen A; Pantalone KM; Galindo RJ; Cui X; Huh R; Hemmingway A; Fernández Landó L; Patel H
    Diabetes Ther; 2023 May; 14(5):925-936. PubMed ID: 37000390
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
    De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
    Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective.
    De Block C; Bailey C; Wysham C; Hemmingway A; Allen SE; Peleshok J
    Diabetes Obes Metab; 2023 Jan; 25(1):3-17. PubMed ID: 35929488
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of the Dual Glucose‐Dependent Insulinotropic Peptide/Gulcagon‐like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta‐analysis.
    Yu D; Shen S; Zhang J; Wang Q
    Clin Ther; 2023 Aug; 45(8):787-796. PubMed ID: 37455226
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes.
    Matza LS; Stewart KD; Landó LF; Patel H; Boye KS
    Patient; 2022 May; 15(3):367-377. PubMed ID: 35513765
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tirzepatide Once Weekly for the Treatment of Obesity.
    Jastreboff AM; Aronne LJ; Ahmad NN; Wharton S; Connery L; Alves B; Kiyosue A; Zhang S; Liu B; Bunck MC; Stefanski A;
    N Engl J Med; 2022 Jul; 387(3):205-216. PubMed ID: 35658024
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4.
    Małecki MT; Batterham RL; Sattar N; Levine JA; Rodríguez Á; Bergman BK; Wang H; Ghimpeteanu G; Lee CJ
    Diabetes Care; 2023 Dec; 46(12):2292-2299. PubMed ID: 37824793
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial.
    Kadowaki T; Chin R; Ozeki A; Imaoka T; Ogawa Y
    Lancet Diabetes Endocrinol; 2022 Sep; 10(9):634-644. PubMed ID: 35914542
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
    Nicholls SJ; Bhatt DL; Buse JB; Prato SD; Kahn SE; Lincoff AM; McGuire DK; Nauck MA; Nissen SE; Sattar N; Zinman B; Zoungas S; Basile J; Bartee A; Miller D; Nishiyama H; Pavo I; Weerakkody G; Wiese RJ; D'Alessio D;
    Am Heart J; 2024 Jan; 267():1-11. PubMed ID: 37758044
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes.
    Ferdinand KC; Dunn J; Nicolay C; Sam F; Blue EK; Wang H
    Cardiovasc Diabetol; 2023 Mar; 22(1):49. PubMed ID: 36894938
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
    Urva S; Quinlan T; Landry J; Ma X; Martin JA; Benson CT
    Clin Pharmacokinet; 2022 Jul; 61(7):1057-1067. PubMed ID: 35674880
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis.
    Tan B; Pan XH; Chew HSJ; Goh RSJ; Lin C; Anand VV; Lee ECZ; Chan KE; Kong G; Ong CEY; Chung HC; Young DY; Chan MY; Khoo CM; Mehta A; Muthiah MD; Noureddin M; Ng CH; Chew NWS; Chin YH
    Int J Obes (Lond); 2023 Aug; 47(8):677-685. PubMed ID: 37253796
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tirzepatide: A Systematic Update.
    Forzano I; Varzideh F; Avvisato R; Jankauskas SS; Mone P; Santulli G
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498958
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials.
    de Mesquita YLL; Pera Calvi I; Reis Marques I; Almeida Cruz S; Padrao EMH; Carvalho PEP; da Silva CHA; Cardoso R; Moura FA; Rafalskiy VV
    Int J Obes (Lond); 2023 Oct; 47(10):883-892. PubMed ID: 37460681
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis.
    Azuri J; Hammerman A; Aboalhasan E; Sluckis B; Arbel R
    Diabetes Obes Metab; 2023 Apr; 25(4):961-964. PubMed ID: 36507900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.